Radionuclide techniques for identifying vulnerable plaque

Journal of Nuclear Medicine

Volumn 48, Issue 11, 2007, Pages 1753-1755

  Dunphy, Mark P S ^a   Schoder, Heiko ^a   Strauss, H William ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; LIPOPROTEIN; RADIOISOTOPE;

APOPTOSIS; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG UPTAKE; HEART RATE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; ISOTOPE LABELING; LIPID STORAGE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBUS; TISSUE DISTRIBUTION; VASCULAR LESION;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID STENOSIS; FLUORODEOXYGLUCOSE F18; HISTORY, 19TH CENTURY; HUMANS; PORTRAITS AS TOPIC; RADIOPHARMACEUTICALS;

EID: 36049029727     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.044651     Document Type: Short Survey

References (50)

1. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med. 2007;48:1800-1815.
2. American Heart Association. Atherosclerosis. Available at: http://www.americanheart.org/presenter.jhtml? identifier54440. Accessed September 18, 2007.
3. Trevino-Trevino AJ. Atherosclerosis and ischemic heart disease: short historical notes. Gac Med Mex. 1996;132:425-429.
4. Marson P, Zanchin G, Stefanutti C. Some historical considerations on the inflammatory theory of atherosclerosis. Reumatismo. 2004;56:215-219.
5. Mayerl C, Lukasser M, Sedivy R, Niederegger H, Seiler R, Wick G. Atherosclerosis research from past to present: on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch. 2006;449:96-103.
6. Libby P. The vascular biology of atherosclerosis. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005:921-937.
7. Schoen FJ, Cotran RS. Blood vessels. In: Cotran RS, Kumar V, Collins T, eds. Robbins' Pathologic Basis of Disease. 6th ed. Philadelphia, PA: W.B. Saunders; 1999:493-542.
8. Lees RS, Lees AM, Strauss HW. External imaging of human atherosclerosis. J Nucl Med. 1983;24:154-156.
9. Sinzinger H, Bergmann H, Kaliman J, Angelberger P. Imaging of human atherosclerotic lesions using 123I-low-density lipoprotein. Eur J Nucl Med. 1986;12:291-292.
10. Fischman AJ, Lees AM, Lees RS, Barlai-Kovach M, Strauss HW. Accumulation of native and methylated low density lipoproteins by healing rabbit arterial wall. Arteriosclerosis. 1987;7:361-366.
11. 125I-BSA. Pathobiology. 2001;69:225-229.
12. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol. 1999;6:41-53.
13. Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol. 2000;20:689-697.
14. Sadeghi MM, Krassilnikova S, Zhang J, et al. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation. 2004;110:84-90.
15. 125I-endothelin-1 accumulation in experimental arterial wall injury. Eur J Nucl Med. 1993;20:1141-1145.
16. Tepe G, Duda SH, Meding J, et al. Tc-99m-labeled endothelin derivative for imaging of experimentally induced atherosclerosis. Atherosclerosis. 2001;157:383-392.
17. 18F]-BQ3020: in vitro characterization and positron emission tomography (microPET). Exp Biol Med (Maywood). 2006;231:736-740.
18. Fischman AJ, Rubin RH, Khaw BA, et al. Radionuclide imaging of experimental atherosclerosis with nonspecific polyclonal immunoglobulin G. J Nucl Med. 1989;30:1095-1100.
19. Ohtsuki K, Hayase M, Akashi K, Kopiwoda S, Strauss HW. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation. 2001;104:203-208.
20. Blankenberg FG, Wen P, Dai M, et al. Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats. Pediatr Radiol. 2001;31:827-835.
21. Vallabhajosula S, Fuster V. Atherosclerosis: imaging techniques and the evolving role of nuclear medicine. J Nucl Med. 1997;38:1788-1796.
22. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology. 2003;229:831-837.
23. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49:1533-1539.
24. 18F-FDG uptake with vascular calcification. J Nucl Med. 2005;46:1278-1284.
25. -/- mice. Eur J Nucl Med Mol Imaging. April 17, 2007 [Epub ahead of print].
26. Davies JR, Rudd JH, Weissberg PL, Narula J. Radionuclide imaging for the detection of inflammation in vulnerable plaques. J Am Coll Cardiol. 2006;47(8 suppl):C57-C68.
27. 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med. 2007;48:227-233.
28. Schafers M, Riemann B, Kopka K, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation. 2004;109:2554-2559.
29. Dietrich T, Perlitz C, Licha K, et al. ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions. Basic Res Cardiol. 2007;102:298-307.
30. Kolodgie FD, Petrov A, Virmani R, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation. 2003;108:3134-3139.
31. Hartung D, Sarai M, Petrov A, et al. Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. J Nucl Med. 2005;46:2051-2056.
32. Strauss HW, Mari C, Patt BE, Ghazarossian V. Intravascular radiation detectors for the detection of vulnerable atheroma. J Am Coll Cardiol. 2006;47(8 suppl):C97-C100.
33. Narula J, Petrov A, Bianchi C, et al. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab′)2 specific for the proliferating smooth muscle cells of human atheroma: imaging with conventional and negative charge-modified antibody fragments. Circulation. 1995;92:474-484.
34. Carrio I, Pieri PL, Narula J, et al. Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. J Nucl Cardiol. 1998;5:551-557.
35. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
36. 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology. 2002;223:446-451.
37. Tawakol A, Migrino RQ, Hoffmann U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol. 2005;12:294-301.
38. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-896.
39. 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med. 2006;47:1845-1850.
40. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-1831.
41. Taegtmeyer H, King LM, Jones BE. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol. 1998;82:54K-60K.
42. 18F-FDG uptake. J Nucl Med. 2007;48:234-239.
43. Fukuchi K, Ohta H, Matsumura K, Ishida Y. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies. Br J Radiol. 2007;80:3-11.
44. Kaneta T, Hakamatsuka T, Takanami K, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med. 2006;20:203-208.
45. de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32:98-101.
46. 18F)-fluorodeoxyglucose positron emission tomography. Circulation. 105:2708-2711.
47. Ohtani T, Ueda Y, Mizote I, et al. Number of yellow plaques detected in a coronary artery is associated with future risk of acute coronary syndrome: detection of vulnerable patients by angioscopy. J Am Coll Cardiol. 2006;47:2194-2200.
48. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol. 2006;98:3Q-9Q.
49. Langer H, Schonberger T, Bigalke B, Gawaz M. Where is the trace? Molecular imaging of vulnerable atherosclerotic plaques. Semin Thromb Hemost. 2007;33:151-158.
50. Elmaleh DR, Fischman AJ, Tawakol A, et al. Detection of inflamed atherosclerotic lesions with diadenosine-5′,5‴-P1,P4-tetraphosphate (Ap4A) and positron-emission tomography. Proc Natl Acad Sci USA. 2006;103:15992-15996.